Search Results
Your search for ,NOt matches 22378 pages
Showing 4701 - 4750PALOMA-2: No Overall Survival Benefit Reported With Palbociclib/Letrozole in Advanced Breast Cancer
The final overall survival analysis of the phase III PALOMA-2 trial has shown no significant benefit for palbociclib given with letrozole, vs letrozole and placebo, as a first-line treatment in hormone receptor–positive, HER2-negative metastatic breast cancer.1 The results were reported at the 2022 ...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the TUXEDO-1 trial1 was Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona. Dr. Oliveira noted that 40% of the 15 patients in TUXEDO-1 had symptomatic disease, and 60% had central nervous system metastases...
T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
Expert Point of View: Debu Tripathy, MD, and Hope S. Rugo, MD, FASCO
The ASCO Post asked Debu Tripathy, MD, Professor and Chair of Medical Breast Oncology at The University of Texas MD Anderson Cancer Center, Houston, and Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education at the University of California San...
Datopotamab Deruxtecan Shows Activity in Advanced Triple-Negative Breast Cancer
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the BEGONIA trial,1 Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, called the activity of the combination of durvalumab and datopotamab deruxtecan (Dato-DXd) “notable,” with a 74% response rate overall,...
BEGONIA Trial Reports Activity With Datopotamab Deruxtecan Plus Durvalumab in Triple-Negative Breast Cancer
Preliminary results of the basket BEGONIA trial showed that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), paired with the immune checkpoint inhibitor durvalumab, has strong activity in advanced or metastatic triple-negative breast cancer among patients not biomarker-selected for...
Expert Point of View: Amy Tiersten, MD and Carlos L. Arteaga, MD
Amy Tiersten, MD, Professor of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, and Carlos L. Arteaga, MD, Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology at The University of Texas Southwestern Medical Center, Dallas,...
PADA-1 Trial: With Early Identification of ESR1 Mutation, Switch to Fulvestrant in Metastatic Breast Cancer
Switching from an aromatase inhibitor to fulvestrant upon early identification of the ESR1 mutation in plasma—before disease progression—doubled progression-free survival in the phase III PADA-1 trial, presented at the 2021 San Antonio Breast Cancer Symposium.1 “PADA-1 is the first trial to...
Expert Point of View: Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is part ...
Dual Checkpoint Inhibitor Therapy Elicits Responses in Highly Mutated Breast Cancer
Patients with advanced HER2-negative metastatic breast cancer and high tumor mutational burden achieved responses—often durable—from treatment with the immunotherapy doublet of nivolumab and ipilimumab, according to results of the phase II NIMBUS trial reported at the 2021 San Antonio Breast Cancer ...
Expert Point of View: Mark E. Robson, MD
“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...
OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer
The OlympiA trial of adjuvant olaparib in patients with HER2-negative, high-risk early-stage breast cancer and BRCA1 and BRCA2 mutations has now demonstrated a significant overall survival benefit, reducing the risk of death over placebo by 32% and yielding an absolute improvement of 3.8% at 3...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer
Use of the first investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly reduced the risk of death or disease progression and lengthened progression-free survival compared with standard-of-care endocrine therapy with fulvestrant or an aromatase inhibitor in...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Researchers Discover Predictive Biomarker of Response to Therapy in Patients With Microsatellite-Stable Metastatic Colorectal Cancer
Researchers have unmasked mutations in the RNF43 gene as predictive biomarkers of a response to treatment with anti-BRAF/EGFR combination therapy in patients with microsatellite-stable BRAF V600E–mutated metastatic colorectal cancer. Data showed that patients with tumors harboring loss-of-function...
Long-Term Outcomes With Minimal-Access vs Conventional Breast Surgery in Stage 0 to III Breast Cancer
In a Chinese single-center, retrospective cohort, propensity score–matched analysis reported in JAMA Surgery, Wan et al found no difference in long-term outcomes, including distant metastasis–free and overall survival, with minimal-access breast surgery vs conventional breast surgery in women with...
Computer Platform May Help Match Patients With Cancer to Targeted Therapy Trials
As more patients with cancer have their tumors genomically profiled and more therapies targeting genomic alterations enter clinical trials, the task of connecting patients with trials for which they are eligible can be especially challenging. The novel computer platform MatchMiner, developed by the ...
Polycystic Ovary Syndrome and Risk of Pancreatic Cancer
In a single-center case-control study reported as a research letter in JAMA Oncology, Peeri et al found that women with polycystic ovary syndrome (PCOS) may be at an increased risk of developing pancreatic cancer. Study Details The study involved data from the Memorial Sloan Kettering Cancer Center ...
Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma
In a Chinese single-center phase II trial reported in JAMA Surgery, Wu et al found neoadjuvant intensity-modulated radiotherapy (IMRT) followed by hepatectomy could be an effective treatment option in patients with centrally located hepatocellular carcinoma. Study Details In the study, 38 patients...
Risk of Meningioma in Childhood Cancer Survivors
In a pooled analysis reported in JAMA Oncology, Withrow et al found that increased exposure of the meninges to radiation therapy was associated with an increased risk of developing meningioma in survivors of childhood cancer. Receipt of methotrexate was also associated with increased risk. Study...
Effect of Social Factors on Cancer Screening Rates Across U.S. Counties
Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...
Study Analyzes Postimaging Diagnoses of Pancreatic Cancer
Computed tomography (CT) and magnetic resonance imaging (MRI) scans may miss the detection of some pancreatic cancer tumors, narrowing the window for life-saving curative surgery, according to new research presented at the United European Gastroenterology (UEG) Week 2022 (Abstract OP192). The...
Letrozole/Abemaciclib for Estrogen Receptor–Positive Recurrent Endometrial Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Panagiotis A. Konstantinopoulos, MD, PhD, and colleagues found that letrozole plus abemaciclib produced activity in patients with estrogen receptor (ER)-positive recurrent endometrial cancer. Study Details In the study, 30 patients...
Enfortumab Vedotin-ejfv Plus Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer
In a phase Ib/II study reported in the Journal of Clinical Oncology, Christopher J. Hoimes, MD, and colleagues found that first-line enfortumab vedotin-ejfv plus pembrolizumab produced a high response rate and prolonged response durations in cisplatin-ineligible, previously untreated patients with...
Expert Point of View: James Larkin, PhD and Andrea Cercek, MD
Invited discussant James Larkin, PhD, a clinical researcher at the Royal Marsden Hospital, London, commented on the findings from NICHE-2.1 “These striking data are consistent with the recent report in locally advanced mismatch repair–deficient [dMMR] rectal cancer from Memorial Sloan Kettering.2...
C-Reactive Protein Level and Cognitive Function in Breast Cancer Survivors Aged 60 and Older
As reported in the Journal of Clinical Oncology by Carroll et al, an analysis from the Thinking and Living with Cancer Study has shown higher levels of C-reactive protein (CRP) at baseline and during follow-up among women with stage 0 to III breast cancer diagnosed at age ≥ 60 years vs controls,...
NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer
Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...
Oncologist Participation in Medicare OCM and Patient Receipt of Novel Therapies
In a study reported in JAMA Network Open, Christopher R. Manz, MD, MSHP, and colleagues found that oncologist participation in the Medicare Oncology Care Model (OCM) was not associated with a reduced likelihood of prescribing novel cancer therapies to their patients. As stated by the investigators, ...
Nivolumab/Ipilimumab vs Dabrafenib/Trametinib With Switch at Disease Progression for Metastatic BRAF-Mutant Melanoma
As reported in the Journal of Clinical Oncology by Michael B. Atkins, MD, and colleagues, the phase III DREAMseq trial (ECOG-ACRIN EA6134) showed that first-line treatment with nivolumab plus ipilimumab followed at disease progression with dabrafenib and trametinib improved 2-year overall survival...
Treatments and Outcomes for Locally Advanced Rectal Cancer in Patients Aged 80 and Older
In an analysis of National Cancer Database data reported in JAMA Surgery, Nassoiy et al found that neoadjuvant chemoradiation therapy followed by surgery was associated with higher rates of R0 resection and improved survival vs other treatments in patients aged 80 and older undergoing surgery for...
RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy
The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...
Study Finds Cost of Cancer Care May Impact Health of Low-Income Survivors
The cost of cancer treatment may negatively impact the physical and mental health of survivors who are living in poverty, according to a recent study published by Coughlin et al in the Journal of Oncology Practice. The findings provide important information about the impact social determinants may...
Decrease in Breast Cancer Mortality Rate Continues, but Gap Persists for Black Women: From American Cancer Society Report
Although breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die of the disease, despite a lower incidence, according to findings outlined in the American Cancer Society’s report Breast Cancer Statistics, 2022, and a companion study published by ...
ASCO Treatment Guidelines for HER2-Negative Metastatic Breast Cancer Updated to Reflect New Trastuzumab Deruxtecan Data
Just 1 month after the DESTINY-Breast04 data were presented at the 2022 ASCO Annual Meeting Plenary Session,1 an ASCO expert panel released updated guidance that endorses the adoption of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) into clinical practice for patients with...
Ibrutinib for Pediatric Patients With Chronic Graft-vs-Host Disease
On August 24, 2022, ibrutinib was approved for pediatric patients 1 year of age or older with chronic graft-vs-host disease after failure of one or more lines of systemic therapy.1 A new oral suspension formulation is available. Supporting Efficacy Data Approval was based on findings from the...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
Expert Point of View: Jonathan Ledermann, MD
Jonathan Ledermann, MD, of UCL Cancer Institute University College London, was the formal discussant of both the phase III SOLO1 and PAOLA-1 trials. He was quite enthusiastic about SOLO1: “Perhaps, this is really cure we are seeing.” He also noted that overall survival is still immature and is...
First-Line Maintenance With Olaparib Improved Overall Survival in Subsets of Patients With Advanced Ovarian Cancer in Two Phase III Trials
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2022 Congress.1,2 In the SOLO1 trial,1 more...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD
TROPiCS-02 is a statistically positive trial, with the primary endpoint met and also now with an overall survival gain of 3.2 months,” said the study’s invited discussant Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology, Barcelona. “TROPiCS-02 is...
TROPiCS-02: Sacituzumab Govitecan Improves Overall Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer
An overall survival benefit has now emerged for sacituzumab govitecan-hziy in women with previously treated, hormone receptor–positive/HER2-negative, locally recurrent, inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial.1 The...
Expert Point of View: Mary O’Brien, MD
Formal discussant of the KEYNOTE-189 and KEYNOTE-407 trials, Mary O’Brien, MD, Head of the Lung Unit, Royal Marsden Hospital, NHS Foundation Trust, London, found that both studies showed consistent gains in overall and progression-free survival with pembrolizumab/chemotherapy, but she expressed...
Mechanism Linking Air Pollution to Lung Cancer Identified
Although air pollution is associated with lung cancer, not much has been known about how one leads to the other. For the first time, researchers have identified a mechanism by which particulate matter in the air triggers non–small cell lung cancer (NSCLC) in people who have never smoked. Moreover,...
What Is the Best Induction Regimen for Newly Diagnosed PCNSL?
Primary central nervous system lymphoma (PCNSL) accounts for less than 1% of all non-Hodgkin lymphomas and between 3% and 4% of all brain tumors, with an age-adjusted incidence rate of four cases per million persons per year. Approximately 1,500 new cases are diagnosed each year in the United...
Cancer and Fertility Preservation: Will New Laws Leave Patients Without Options?
The legal climate surrounding reproductive health care and fertility preservation has changed drastically since the June 2022 Supreme Court decision to overturn Roe v Wade, which revoked the constitutional right to abortion. With this ruling, individual state legislatures are now able to pass laws...
Expert Point of View: Alexander M.M. Eggermont, MD; Omid Hamid, MD; and James Larkin, PhD
The results of SWOG S18011 were met with enthusiasm by attendees at the Presidential Symposium of the European Society for Medical Oncology (ESMO) Congress 2022. The ASCO Post captured the thoughts of several melanoma experts, who had somewhat different ideas about the immediate clinical...
SWOG S1801: Addition of Neoadjuvant Pembrolizumab to Adjuvant Pembrolizumab Yields Benefits in High-Risk Resectable Melanoma
In resectable stage III to IV melanoma, three cycles of neoadjuvant pembrolizumab followed by adjuvant pembrolizumab was significantly more beneficial than adjuvant pembrolizumab alone, based on the results of the phase II SWOG S1801 trial presented in a Presidential Symposium at the European...
